Severe psoriasis treated with a new macrolide: Everolimus

E. Frigerio, M. D. Colombo, C. Franchi, A. Altomare, C. Garutti, G. F. Altomare

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.

Original languageEnglish
Pages (from-to)372-374
Number of pages3
JournalBritish Journal of Dermatology
Volume156
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Macrolides
Psoriasis
Cyclosporine
Immune System Diseases
Sirolimus
Immunosuppressive Agents
Switzerland
Transplants
Kidney
Everolimus
Therapeutics

Keywords

  • Ciclosporin
  • Everolimus
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology

Cite this

Severe psoriasis treated with a new macrolide : Everolimus. / Frigerio, E.; Colombo, M. D.; Franchi, C.; Altomare, A.; Garutti, C.; Altomare, G. F.

In: British Journal of Dermatology, Vol. 156, No. 2, 02.2007, p. 372-374.

Research output: Contribution to journalArticle

Frigerio, E, Colombo, MD, Franchi, C, Altomare, A, Garutti, C & Altomare, GF 2007, 'Severe psoriasis treated with a new macrolide: Everolimus', British Journal of Dermatology, vol. 156, no. 2, pp. 372-374. https://doi.org/10.1111/j.1365-2133.2006.07602.x
Frigerio, E. ; Colombo, M. D. ; Franchi, C. ; Altomare, A. ; Garutti, C. ; Altomare, G. F. / Severe psoriasis treated with a new macrolide : Everolimus. In: British Journal of Dermatology. 2007 ; Vol. 156, No. 2. pp. 372-374.
@article{d7dcdeb7444c4062a579b6ceece35c4c,
title = "Severe psoriasis treated with a new macrolide: Everolimus",
abstract = "Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican{\circledR}; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.",
keywords = "Ciclosporin, Everolimus, Psoriasis",
author = "E. Frigerio and Colombo, {M. D.} and C. Franchi and A. Altomare and C. Garutti and Altomare, {G. F.}",
year = "2007",
month = "2",
doi = "10.1111/j.1365-2133.2006.07602.x",
language = "English",
volume = "156",
pages = "372--374",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Severe psoriasis treated with a new macrolide

T2 - Everolimus

AU - Frigerio, E.

AU - Colombo, M. D.

AU - Franchi, C.

AU - Altomare, A.

AU - Garutti, C.

AU - Altomare, G. F.

PY - 2007/2

Y1 - 2007/2

N2 - Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.

AB - Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.

KW - Ciclosporin

KW - Everolimus

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=33846189774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846189774&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2006.07602.x

DO - 10.1111/j.1365-2133.2006.07602.x

M3 - Article

C2 - 17223881

AN - SCOPUS:33846189774

VL - 156

SP - 372

EP - 374

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -